Earnings Summary: C4 Therapeutics Q4
Benzinga Insights 8 months ago
Earnings
The Q4 earnings report for C4 Therapeutics (NASDAQ:CCCC) was released on Thursday, February 26, 2026 at 07:00 AM.
Here's what investors need to know about the latest announcement.
Earnings
C4 Therapeutics beat estimated earnings by 56.1%, reporting an EPS of $-0.18 versus an estimate of $-0.41.
Revenue was up $5.84 million from the same period last year.
Earnings History Overview
Last quarter the company missed on EPS by $0.02 which was followed by a 1.68% drop in the share price the next day.
Here's a look at C4 Therapeutics's past performance:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.42 | -0.38 | -0.42 | -0.37 |
| EPS Actual | -0.44 | -0.37 | -0.37 | -0.49 |
| Revenue Estimate | 6.37M | 6.53M | 2.95M | 3.60M |
| Revenue Actual | 11.23M | 6.46M | 7.24M | 5.18M |
Listen to the earnings announcement yourself by clicking here.
To track all earnings releases for C4 Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.